<code id='BE8D9524C4'></code><style id='BE8D9524C4'></style>
      • <acronym id='BE8D9524C4'></acronym>
      <center id='BE8D9524C4'><center id='BE8D9524C4'><tfoot id='BE8D9524C4'></tfoot></center><abbr id='BE8D9524C4'><dir id='BE8D9524C4'><tfoot id='BE8D9524C4'></tfoot><noframes id='BE8D9524C4'>
      • <optgroup id='BE8D9524C4'><strike id='BE8D9524C4'><sup id='BE8D9524C4'></sup></strike><code id='BE8D9524C4'></code></optgroup>
        5. <b id='BE8D9524C4'><label id='BE8D9524C4'><select id='BE8D9524C4'><dt id='BE8D9524C4'><span id='BE8D9524C4'></span></dt></select></label></b><u id='BE8D9524C4'></u>
          <i id='BE8D9524C4'><strike id='BE8D9524C4'><tt id='BE8D9524C4'><pre id='BE8D9524C4'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-01 03:28:50 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：7667
                                  
                                    
          
                                   
          Alastair Grant/AP
          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.
          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.
          advertisement
          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Bacterial infection may be ‘key event’ in endometriosis, study says
                                
                            
          Next article：  
                                      
                                          Drug repurposing or repositioning? The language matters
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles